5-11 There were many Jеws staying in Jerusalem just then, devout pilgrims from all over the world. When they heard the sound, they came on the run. Then when they heard, one after another, their own mother tongues being spoken, they were blown away. They couldn’t for the life of them figure out what was going on, and kept saying, “Aren’t these all Galileans? How come we’re hearing them talk in our various mother tongues? Parthians, Medes, and Elamites; Visitors from Mesopotamia, Judea, and Cappadocia, Pontus and Asia, Phrygia and Pamphylia, Egypt and the parts of Libya belonging to Cyrene; Immigrants from Rome, both Jеws and proselytes; Even Cretans and Arabs! “They’re speaking our languages, describing God’s mighty works!” 12 Their heads were spinning; they couldn’t make head or tail of any of it. They talked back and forth, confused: “What’s going on here?”

• We had 8 healthy looking seedlings in a pot
• Transplanted cucumber seedlings on Sunday
• Immediate shock to the system!
• 5 are struggling to recover
• 3 are looking like they might make it

Abstract

Background:
Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the ‘psychedelic afterglow’, have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period.
Objectives:
This systematic review provides an overview of subacute effects of psychedelics.
Methods:
Electronic databases (MEDLINE, Web of Science Core Collection) were searched for studies that assessed the effects of psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT, mescaline, or ayahuasca) on psychological outcome measures and subacute adverse effects in human adults between 1950 and August 2021, occurring between 1 day and 1 month after drug use.
Results:
Forty-eight studies including a total number of 1,774 participants were eligible for review. Taken together, the following subacute effects were observed: reductions in different psychopathological symptoms; increases in wellbeing, mood, mindfulness, social measures, spirituality, and positive behavioral changes; mixed changes in personality/values/attitudes, and creativity/flexibility. Subacute adverse effects comprised a wide range of complaints, including headaches, sleep disturbances, and individual cases of increased psychological distress.
Discussion:
Results support narrative reports of a subacute psychedelic ‘afterglow’ phenomenon comprising potentially beneficial changes in the perception of self, others, and the environment. Subacute adverse events were mild to severe, and no serious adverse events were reported. Many studies, however, lacked a standardized assessment of adverse effects. Future studies are needed to investigate the role of possible moderator variables and to reveal if and how positive effects from the subacute window may consolidate into long-term mental health benefits.

Figure 2

^a Since the domain of Personality/Values/Attitudes does not qualify for the dichotomous classification of ‘increase/decrease’, all changes were summarized with the label ‘other change’. Nine studies collected data on broad personality measures, e.g. using the Minnesota Multiphasic Personality Inventory,⁷⁰ or the revised NEO Personality Inventory.⁷¹ Four of those studies (44%) reported subacute effects: one study each reported a decrease in hypochondriasis,²⁵ an increase in openness,⁴⁰ an increase in conscientiousness,⁵⁷ and a decrease in neuroticism, and an increase in agreeableness.⁶⁰ Six studies reported on 12 outcome measures assessing specific personality traits/values/attitudes. Except optimism, each of them was assessed only once: an increase was reported in religious values,²³ optimism,^40,72 nature relatedness,⁴⁷ absorption, dispositional positive emotions,⁵⁷ self-esteem, emotional stability, resilience, meaning in life, and gratitude.⁶⁵ A decrease was reported in authoritarianism⁴⁷ and pessimism.⁴⁸ Four studies reported on the two subscales ‘attitudes toward life and self’ of the Persisting Effects Questionnaire. All reported increased positive attitudes,^3,5,34,49 and one study reported increased negative attitudes at low doses of psilocybin.^34
b Six out of 10 studies reported effects in the outcome domain of mood: one study reported an increase in dreaminess (shown as ‘other change’),³⁰ one study reported a subacute decrease in negative affect, tension, depression, and total mood disturbances,⁵⁷ and four studies reported positive mood changes.^3,5,34,49
c One study observed an increase in convergent and divergent thinking at different subacute assessment points and was therefore classified half as ‘increase’ and half as ‘decrease’.^54
d Four studies collected complaints in the subacute follow-up using a standardized list of complaints: three of these studies reported no change,^29,39,41 one study reported an increase in complaints after 1 day but not 1 week.²⁸ One other study reported a reduction in migraines.⁶⁷ One study assessed general subjective drug effects lasting into the subacute follow-up period and reported no lasting subjective drug effects.^39
e Johnson et al.³ report a peak of withdrawal symptoms 1 week after the substance session. However, since the substance session coincided with the target quit date of tobacco, this was not considered a subacute effect of psilocybin but of tobacco abstinence.
^f Including intelligence, visual perception,²⁷ and a screening for cognitive impairments.⁵⁵

Conclusion

If subacute effects occurred after using psychedelics in a safe environment, these were, for many participants, changes toward indicators of increased mental health and wellbeing. The use of psychedelics was associated with a range of subacute effects that corroborate narrative reports of a subacute afterglow phenomenon, comprising reduced psychopathology, increased wellbeing, and potentially beneficial changes in the perception of self, others, and the environment. Mild-to-severe subacute adverse events were observed, including headaches, sleep disturbances, and individual cases of increased psychological distress, no serious adverse event was reported. Since many studies lacked a standardized assessment of adverse events, results might be biased, however, by selective assessment or selective reporting of adverse effects and rare or very rare adverse effects may not have been detected yet due to small sample sizes.
Future studies are needed to investigate the role of possible moderator variables (e.g. different psychedelic substances and dosages), the relationship between acute, subacute, and long-term effects, and whether and how the consolidation of positive effects from the subacute window into long-term mental health benefits can be supported.

Source

• The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics Therapeutic Advances in Psychopharmacology [May 2023]

Further Research

• The AfterGlow ‘Flow State’ Effect ☀️🧘; Glutamate Modulation: Precursor to BDNF (Neuroplasticity) and GABA; Psychedelics Vs. SSRIs MoA*; No AfterGlow Effect/Irritable❓ Try GABA Cofactors; Further Research: BDNF ⇨ TrkB ⇨ mTOR Pathway.
• Although new (flawed?) research may indicate oxytocin also involved. To Take A Deep-Dive.

Introduction:

1. Continuous Learning and Adaptability:

2. Leadership and Teamwork:

3. Strategic Thinking and Problem-Solving:

4. Effective Communication and Influencing:

5. Strategic Networking and Personal Branding:

Conclusion: